Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is experiencing a positive outlook due to an upward revision of its fiscal year 2026 earnings per share (EPS) estimates, indicating improved financial expectations amidst an expanding share count. The anticipated FDA approval of the MyoVista device and the rollout of the MyoVista Insights cloud software platform present a significant market opportunity, likely positioning the company for enhanced growth in the coming years. Additionally, the new price target of $9.20 suggests substantial potential upside, supported by net present value analysis reflecting investor confidence in the company's innovative AI-ECG diagnostic solutions.

Bears say

HeartSciences Inc. is facing significant financial challenges, as indicated by a substantial downward revision of its FY2026 revenue estimate from $1.2 million to only $0.1 million, primarily due to delays with the FDA. Additionally, the company is exposed to multiple risks, including liquidity and balance sheet issues, the potential for product candidates to fail in clinical trials, and challenges related to regulatory approvals and commercialization of its technologies. The myriad of risks posed by competition, changes in macroeconomic factors, and evolving investor sentiment further contribute to a negative outlook for the stock.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.